摘要
目的观察阿托伐他汀对实验性自身免疫性脑脊髓炎单核细胞趋化蛋白-1表达(MCP-1)的影响,并探讨其治疗机制。方法建立EAE模型,应用阿托伐他汀进行干预,观察其对大鼠发病率、神经功能评分和病理学改变的影响,并测定单核细胞趋化蛋白-1(MCP-1)在体内的表达及变化。结果阿托伐他汀高剂量治疗组大鼠发病率降低,神经功能评分减少,病理学改变减轻,血清中MCP-1的表达减少。结论阿托伐他汀能改善EAE的临床表现,但其作用呈剂量相关性,其机制可能与减少MCP-1的表达有关。
Objective To observe the effects of atorvastatin on the experimental autoimmune encephalomye- litis(EAE) and study its mechanism. Methods The rat model of EAE was established and then atorv.astatin was administered for interventional treatment. The rats were examined for the incidence, the development of neurological signs, changes of histopathology and the expression of MCP- 1. Results The rats in high dose atorvastatin group had a lower incidence, decreased inflammatory reaction, lower level of MCP- 1. Conclusions Atorvastatin can improve the clinical neurological functions of rat EAE model and the effect is dose- dependent. The effect of atorvastatin on EAE may be related to decreasing the expression of MCP- 1.
出处
《中国煤炭工业医学杂志》
2013年第6期975-977,共3页
Chinese Journal of Coal Industry Medicine
基金
河北省2010年医学科学研究重点课题计划(编号:20100473)
关键词
实验性自身免疫性脑脊髓炎
多发性硬化
阿托伐他汀
单核细胞趋化蛋白-1
Atorvastatin~ Experimental autoimmune encephalomyelitis(EAE) ~ Multiple sclerosis~ Mono-cyte chemoattractant protein- 1 (MCP- 1)